Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RADX | 6-K | bearish | 6/10 | Radiopharm Theranostics announced a dilutive capital raise comprising a US$4.1 million registered direct offering of ADS | Jul 24, 2026 |
| QUCY | 8-K | neutral | 4/10 | Quantum Cyber N.V. (QUCY) filed an 8-K furnishing an investor presentation that details its pivot from a former life-sci | Jul 24, 2026 |
| SXT | 8-K | bullish | 7/10 | Sensient Technologies reported a strong Q2 2026 beat, with EPS of $1.20 (+16.4% vs consensus of $1.03) and revenue of $4 | Jul 24, 2026 |
| DYAI | 8-K | neutral | 4/10 | Dyadic International announced that Nasdaq confirmed the company has regained compliance with Listing Rules 5550(a)(2) a | Jul 24, 2026 |
| NAMS | 8-K | bullish | 7/10 | NewAmsterdam Pharma announced that the EMA's CHMP has adopted a positive opinion recommending marketing authorization fo | Jul 24, 2026 |
| DARE | 8-K | neutral | 2/10 | Dare Bioscience filed an 8-K with a corporate investor presentation dated July 24, 2026, under Item 7.01 Regulation FD. | Jul 24, 2026 |
| VIR | 8-K | neutral | 3/10 | Vir Biotechnology disclosed that CFO Jason O'Byrne will step down on August 3, 2026 to pursue another opportunity, with | Jul 24, 2026 |
| SXTC | 424B5 | bearish | 8/10 | China SXT Pharmaceuticals filed a 424B5 prospectus supplement for a $9M registered direct offering of 4.5M units at $2.0 | Jul 24, 2026 |
| SCTX | EFFECT | neutral | 5/10 | Scribe Therapeutics' S-1 registration statement for its IPO was declared effective by the SEC on July 23, 2026. This cle | Jul 24, 2026 |
| NYB | EFFECT | neutral | 4/10 | The SEC declared effective the registration statement (File No. 333-294461) for NYB Holdings Ltd, a Singapore-based medi | Jul 24, 2026 |
| OTLK | 8-K | neutral | 3/10 | Outlook Therapeutics granted stock options to its CEO (100,000 options) and CFO (210,078 options) at $1.4304/share, vest | Jul 24, 2026 |
| INSM | INST-CLUSTER | neutral | 4/10 | A mixed institutional cluster in INSM for 2026-Q2 shows 4 buyers adding $11.3M in net new holdings (led by Assenagon Ass | Jul 24, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt sold $3.4M worth of UTHR shares across 9 open-market trades on July 22, 2026, at prices ranging fr | Jul 24, 2026 |
| CDXS | PRESS-RELEASE | bearish | 6/10 | Codexis priced a dilutive underwritten public offering of 16,666,667 shares at $1.50/share, expected to raise ~$23.1M in | Jul 23, 2026 |
| SCTX | 3, PRESS-RELEASE | bullish | 7/10 | Scribe Therapeutics (SCTX) priced its upsized IPO of 8,580,000 shares at $15.00/share, raising $128.7M in gross proceeds | Jul 23, 2026 |
| ARTV | INSIDER-BUY | bullish | 7/10 | RA Capital Management, a 10% owner and director, purchased a total of ~281K shares of Artiva Biotherapeutics for ~$2.58M | Jul 23, 2026 |
| ADPT | CLUSTER | neutral | 4/10 | Three C-suite executives at Adaptive Biotechnologies sold a total of $8.56M in shares over a one-week window. The sales | Jul 23, 2026 |
| MLYS | CLUSTER | neutral | 2/10 | Two C-suite insiders at Mineralys Therapeutics sold shares totaling ~$211K in open-market transactions after exercising | Jul 23, 2026 |
| AEON | 8-K | bearish | 5/10 | AEON Biopharma completed the partial exercise of the over-allotment option from its July 15, 2026 public offering, issui | Jul 23, 2026 |
| GRDX | 8-K | neutral | 5/10 | GridAI Technologies Corp. (GRDX) made a $2,000,000 secured convertible loan to Pronghorn Resources, LLC on July 17, 2026 | Jul 23, 2026 |
| JNJ | COURT-RULING | bearish | 7/10 | A federal magistrate judge granted Johnson & Johnson's motion for an order to show cause in the talc MDL, requiring all | Jul 23, 2026 |
| LODE | PRESS-RELEASE | mixed | 5/10 | Comstock reported Q2 2026 EPS of -$0.16, missing consensus of -$0.12 by 35.8%, with no revenue disclosed. The quarter in | Jul 23, 2026 |
| KRYS | PRESS-RELEASE | neutral | 1/10 | Krystal Biotech, Inc. announced it will report its Q2 2026 results on August 3, 2026. | Jul 23, 2026 |
| CYTK | PRESS-RELEASE | neutral | 1/10 | Cytokinetics, Incorporated announced it will report its Q2 results on August 6, 2026. | Jul 23, 2026 |
| CUVL | 6-K | mixed | 5/10 | Clinuvel Pharmaceuticals announced a strategic reorganization effective January 1, 2027, including a 10%-20% workforce r | Jul 23, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's filed two 6-Ks on July 23, 2026, reporting the outcome of its 42nd Annual General Meeting. Shareholders appr | Jul 23, 2026 |
| IRD | 144 | neutral | 2/10 | Joseph K. Schachle, an officer of Opus Genetics, filed a Form 144 notice of intent to sell 4,644 shares of common stock, | Jul 23, 2026 |
| IRD | 144 | neutral | 2/10 | Opus Genetics (IRD) insider/officer Benjamin R. Yerxa filed a Form 144 notice to sell 7,429 shares for tax withholding r | Jul 23, 2026 |
| OPK | PRESS-RELEASE | neutral | 1/10 | OPKO Health, Inc. announced it will report its Q2 2026 results on July 27, 2026. | Jul 23, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's Laboratories filed a Form 6-K reporting a routine auditor change from Ernst & Young Associates LLP to Deloit | Jul 23, 2026 |